Status:
TERMINATED
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Lead Sponsor:
Celgene
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multip...
Detailed Description
The dose escalation parts (Part A with CC-93269 administered intravenous (IV) and Part C subcutaneous (SC)) of the study will evaluate the safety and tolerability of escalating doses of CC-93269, admi...
Eligibility Criteria
Inclusion
- History of multiple myeloma with relapsed and refractory disease
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Must have measurable disease as determined by the central laboratory
Exclusion
- Symptomatic central nervous system involvement of multiple myeloma
- Prior autologous stem cell transplant ≤ 3 months prior
- Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior
- History of concurrent second cancers requiring active, ongoing systemic treatment
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
April 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2025
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT03486067
Start Date
April 3 2018
End Date
March 18 2025
Last Update
April 17 2025
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 105
Birmingham, Alabama, United States, 35294
2
Local Institution - 103
San Francisco, California, United States, 94143
3
Local Institution - 107
New Haven, Connecticut, United States, 06510
4
Local Institution - 106
Atlanta, Georgia, United States, 30322